NMM
RVNC

Naples Money Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Naples Money Management’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$1.56K Hold
300
– – ﹤0.01% 322
2024
Q2 		$771 Hold
300
– – ﹤0.01% 361
2024
Q1 		$1.48K Hold
300
– – ﹤0.01% 335
2023
Q4 		$2.64K Buy
+300
New +$2.46K ﹤0.01% 304

Other funds holding RVNC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

Naples Money Management's RVNC Position: Q3 2024 in Review

Naples Money Management held its Revance Therapeutics, Inc. (RVNC) position steady in Q3 2024 at 300 shares worth $1.56K. The position accounts for ﹤0.01% of the portfolio, ranked #322.

Naples Money Management first reported a position in RVNC in Q4 2023 and has held it in 4 quarters since. The position peaked at $2.64K in Q4 2023. 201 funds tracked by Wall St. Rank hold RVNC as of Q3 2024.

  • Naples Money Management held 300 shares of Revance Therapeutics, Inc. worth $1.56K as of Q3 2024.
  • Naples Money Management left its Revance Therapeutics, Inc. share count unchanged in Q3 2024.
  • Revance Therapeutics, Inc. made up ﹤0.01% of Naples Money Management's portfolio in Q3 2024, its #322 holding.
  • Naples Money Management first reported a position in Revance Therapeutics, Inc. in Q4 2023 and has held it in 4 quarters since.
  • Naples Money Management's Revance Therapeutics, Inc. position peaked at $2.64K in Q4 2023.
  • 201 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2024.

Based on Naples Money Management's 13F filing for Q3 2024, filed 12 Nov 2024.